Cannabis Compound Reduces Agitation In Alzheimer’s Patients
Wednesday, August 15, 2018
Credit: Courtesy of Alzheimer's Association
Heather Snyder, Ph.D., senior director of medical and scientific relations, Alzheimer’s Association
A recent study found that patients with Alzheimer's disease who took a synthetic cannabis compound experienced less agitation, one of the most common symptoms of the disease.
That research is just one of the takeaways from this year’s Alzheimer’s Association International Conference. The goal of the conference is to advance dementia science in an effort to learn methods of prevention, treatment and improved diagnosis.
A roundup of the new research will be presented at an event at the University of San Diego Wednesday at 6 p.m. The event is open to the public, but attendees are encouraged to make a reservation by calling 800-272-3900.
Heather Snyder, who heads medical and scientific relations for the Alzheimer's Association, joins Midday Edition on Wednesday with an overview of the latest research on Alzheimer's disease.
To view PDF documents, Download Acrobat Reader.